ProtAffin
Vienna, Austria
Team Members:
Bruce Booth
Sector: Life Sciences
Sub-Sector: Therapeutics
http://www.protaffin.com
ProtAffin AG is using its unique protein engineering technology to develop a novel class of products for inflammatory diseases such as COPD and asthma, both billion dollar markets. The company's technology represents a shift in altering protein-glycan interactions, and could lead to disease modifying treatments, a clear unmet need for these indications.